Click here for printer friendly page
BioXell lists on Swiss Stock Exchange26/06/2006. Source: AltAssets. 
 Life Sciences Partners, the pan-European life science venture capital group, has announced the IPO of BioXell, its Italian-based portfolio company, on the main board of the Swiss Stock Exchange.
BioXell develops therapeutics for urology, inflammation, and related disorders. The offer price per ordinary share of BioXell was set at CHF 44.
The bank syndicate, consisting of Credit Suisse , Bank am Bellevue, Société Générale Corporate & Investment Banking and Pacific Growth Equities LLC has placed a total of 1,313,100 new ordinary shares of BioXell. In addition, BioXell has granted the managers of the offering an over-allotment option of up to 15 per cent of the offer size or 196,965 shares.
The offered shares represented 25 per cent of the company's issued share capital as outstanding after the offering, or approximately 28 per cent if the over-allotment option is exercised in full. Trading of BioXell's shares on the main board of the Swiss Exchange began on June 22, 2006.
BioXell intends to use the proceeds of its IPO primarily to support ongoing and new clinical development and research programs and for general corporate purposes.
Prior to the public offering, BioXell had raised a total of approximately €76m through specialised healthcare investors including LSP, MPM Capital, Index Ventures, BB BIOTECH, AlpInvest Partners, and TVM Capital.
BioXell has sites in Milan, Italy and Nutley, NJ, USA.
LSP has offices in Amsterdam, Munich and Boston. The group has invested in 40 life sciences companies with close to 500m assets under management.
Copyright © 2006 AltAssets
|
